These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15616894)

  • 1. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
    Kitano M; Ogata A; Sekiguchi M; Hamano T; Sano H
    J Bone Miner Metab; 2005; 23(1):48-52. PubMed ID: 15616894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
    Ogata A; Kitano M; Hashimoto N; Iwasaki T; Hamano T; Kakishita E
    J Bone Miner Metab; 2002; 20(4):240-2. PubMed ID: 12115071
    [No Abstract]   [Full Text] [Related]  

  • 4. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
    Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
    Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma.
    Sondergaard TE; Pedersen PT; Andersen TL; Søe K; Lund T; Ostergaard B; Garnero P; Delaisse JM; Plesner T
    Hematol Oncol; 2009 Mar; 27(1):17-22. PubMed ID: 18668701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone markers in multiple myeloma.
    Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
    Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
    J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity.
    Manicourt DH; Brasseur JP; Boutsen Y; Depreseux G; Devogelaer JP
    Arthritis Rheum; 2004 Nov; 50(11):3690-7. PubMed ID: 15529370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma.
    Pittari G; Costi D; Raballo M; Maulucci L; Baroni MC; Mangoni M
    Acta Biomed; 2006 Aug; 77(2):81-4. PubMed ID: 17172186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.